NOT YET RECRUITING
NCT07949760
WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD Trial
This phase II trial tests how well the WOKVAC vaccine works in preventing brain metastases in patients with HER2 positive, hormone receptor negative or low breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). WOKVAC is a vaccine made from tumor-associated proteins, pUMVC3, IGFBP2, HER2, and IGF1R, and may help the body build an effective immune response to kill tumor cells. Sargramostim is a substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets It is a cytokine that is a type of hematopoietic (blood forming) agent. Giving WOKVAC mixed with sargramostim may help prevent the development of brain metastases in patients with HER2 positive, hormone receptor negative or metastatic breast cancer.
Gender: All
Ages: 18 Years - Any
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic HER2-Positive Breast Carcinoma
Metastatic Hormone Receptor-Negative Breast Carcinoma